Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. But so far, the company is ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. The latest readout positions Breyanzi for a ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $57.42.

A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to ...

Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis. Adjusted EPS was $1.67, topping the $1.46 consensus but ...

Revenue: US$48.3b (up 7.3% from FY 2023). Net loss: US$8.95b (down by 212% from US$8.03b profit in FY 2023). US$4.41 loss per share (down from US$3.88 profit in FY 2023). Revenue exceeded analyst ...

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025 ...

Pharma giant Bristol Myers Squibb is planning another round of cost cutting as part of a broader restructuring plan. Under the “strategic productivity initiative” announced Feb. 6, the ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag ...